TAF7L: A Potential Drug Target and Biomarker (G54457)

Target Name: TAF7L

NCBI ID: G54457

TAF7L

TAF7L: A Potential Drug Target and Biomarker

TAF7L, short for T-cell activation factor 7-like, is a protein that plays a crucial role in the regulation of T cells, a type of white blood cell that plays a vital role in the immune system. TAF7L has been identified as a potential drug target and biomarker for several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

TAF7L is a cytokine-producing protein that is expressed in various tissues, including the brain, pancreas, and skin. It is a key regulator of T cell development and function, and has been implicated in several diseases. TAF7L has been shown to regulate the expression of genes involved in cell adhesion, differentiation, and survival.

One of the most significant findings related to TAF7L is its role in cancer. Many studies have shown that TAF7L is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. TAF7L has also been shown to promote the growth and survival of cancer cells.

The potential drug targets for TAF7L are numerous. One of the most promising targets is the inhibition of TAF7L, which has been shown to have therapeutic effects in various types of cancer. Another potential target is the regulation of TAF7L expression, which could be achieved through the use of drugs that target the protein itself or its downstream targets.

TAF7L has also been shown to be involved in several autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. In these disorders, T cells play a crucial role in causing inflammation and damage to the body's tissues. The potential drug targets for these disorders are also numerous, and include the inhibition of TAF7L-mediated signaling pathways.

In addition to its role in autoimmune disorders, TAF7L has also been implicated in several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. In these disorders, T cells are thought to play a crucial role in the immune response and the destruction of neurodegenerate particles. The potential drug targets for these disorders are also numerous, and include the inhibition of TAF7L-mediated signaling pathways.

Overall, TAF7L is a protein that has significant implications for the development of new drugs and therapies. Its role as a potential drug target and biomarker makes it an attractive target for research into the treatment of various diseases. Further studies are needed to fully understand the role of TAF7L in disease and to develop effective treatments.

Protein Name: TATA-box Binding Protein Associated Factor 7 Like

Functions: Probably functions as a spermatogenesis-specific component of the DNA-binding general transcription factor complex TFIID, a multimeric protein complex that plays a central role in mediating promoter responses to various activators and repressors. May play a role in spermatogenesis (By similarity)

The "TAF7L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAF7L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets